文献速递重症综合管理与镇静镇痛

抗阻训练与β-羟基-β-甲基丁酸对危重症功能恢复的作用:多中心2×2析因随机试验

Resistance training and β-hydroxy-β-methylbutyrate for functional recovery in critical illness: a multicenter 2 × 2 factorial randomized trial.
PubMed 文献 · Crit Care · 2025-10-16
一句话结论在成人ICU患者中,抗阻训练显著改善出院时躯体功能并降低6个月和12个月死亡率,而β-羟基-β-甲基丁酸仅轻度改善相位角和疲劳,两者无协同效应。

该多中心、开放标签、2×2析因随机对照试验纳入266例成人ICU患者,随机接受抗阻训练、β-羟基-β-甲基丁酸(HMB)补充、联合干预或标准治疗,干预自ICU开始持续至出院。主要终点为出院时6分钟步行距离(6MWD)和简易体能状况量表(SPPB)。结果显示,与未接受抗阻训练者相比,抗阻训练组SPPB评分平均差1.32分(P=0.003)、6MWD延长56.20米(P<0.001),并降低6个月死亡率(OR 0.51,P=0.011)和12个月死亡率(OR 0.55,P=0.014),同时增加握力、四肢骨骼肌量和骨骼肌指数。HMB仅轻度增加相位角(0.367,P=0.020)和减轻疲劳(–1.069分,P=0.005),未检测到交互作用。

要点

  • 在成人ICU患者中,抗阻训练较未接受抗阻训练者显著改善出院时SPPB评分(平均差1.32分,P=0.003)和6MWD(延长56.20米,P<0.001)。
  • 抗阻训练与6个月死亡率降低相关(OR 0.51,P=0.011),与12个月死亡率降低相关(OR 0.55,P=0.014)。
  • 抗阻训练增加握力(3.19 kg,P=0.008)、四肢骨骼肌量(0.997 kg,P=0.005)和骨骼肌指数(0.428 kg/m²,P=0.025)。
  • HMB补充仅轻度增加相位角(0.367,P=0.020)和减轻疲劳(–1.069分,P=0.005),对其他结局无影响;134例接受HMB的患者中3例发生高血糖。
  • 未检测到抗阻训练与HMB之间的交互作用,联合干预无协同获益。

适用人群与场景

  • 成人ICU患者,共266例,来自多中心。
  • 干预自ICU开始并持续至出院。

处置流程与药物剂量

  • 抗阻训练:自ICU开始持续至出院,具体方案原文未详述。
  • HMB补充:自ICU开始持续至出院,134例接受HMB的患者中3例发生高血糖。

研究设计与关键结果

  • 多中心、开放标签、2×2析因随机对照试验,盲法评估结局,纳入266例成人ICU患者,随机分为抗阻训练组、HMB组、联合干预组或标准治疗组。
  • 主要终点:出院时SPPB评分平均差1.32分(P=0.003),6MWD延长56.20米(P<0.001),均为抗阻训练组优于未接受抗阻训练组。
  • 关键次要终点:抗阻训练组6个月死亡率OR 0.51(P=0.011)、12个月死亡率OR 0.55(P=0.014);握力增加3.19 kg(P=0.008)、四肢骨骼肌量增加0.997 kg(P=0.005)、骨骼肌指数增加0.428 kg/m²(P=0.025);疲劳减轻、睡眠质量和心理症状改善(P<0.05),但对认知或整体生活质量无影响。
  • HMB组相位角增加0.367(P=0.020)、疲劳减轻–1.069分(P=0.005),其他结局无影响;134例接受HMB的患者中3例发生高血糖。
  • 未检测到抗阻训练与HMB的交互作用。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、2×2析因随机对照试验,盲法评估结局,意向性治疗分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在成人ICU患者中,抗阻训练自ICU开始持续至出院可改善出院时躯体功能、增加肌肉量并降低6个月和12个月死亡率。
  • HMB补充仅轻度改善相位角和疲劳,与抗阻训练联合无协同获益。
  • 作者认为,该试验提供了抗阻训练改善躯体功能、增加肌肉量、改善患者报告结局并降低6个月和12个月死亡率的新证据。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Combined nutrition and rehabilitation is a top research priority for ICU-acquired weakness, yet the optimal strategy and clinical benefits remain unclear. This study aimed to evaluate the independent and combined effects of resistance training (RT) and β-hydroxy-β-methylbutyrate (HMB) in critically ill adults. METHODS: We conducted a multicenter, open-label, 2 × 2 factorial randomized controlled trial with blinded outcome assessment in 266 adult ICU patients. Participants were randomized to receive RT, HMB supplementation, combined interventions, or standard care. Treatments began in the ICU and continued until discharge. Primary outcomes at discharge included six-minute walk distance (6MWD) and the Short Physical Performance Battery (SPPB). Secondary outcomes included muscle strength and mass, patient-reported outcomes, and mortality at 1, 6, and 12 months. Analyses followed the intention-to-treat principle, using linear mixed-effects models to estimate the independent and interactive effects of RT and HMB. RESULTS: RT significantly improved physical function at discharge, with higher SPPB scores (mean difference:1.32 points; P = 0.003) and longer 6MWD (56.20 m; P < 0.001), compared with patients who did not receive RT. It was associated with lower 6-month (OR, 0.51; P = 0.011) and 12-month mortality (OR, 0.55; P = 0.014), and increased grip strength (3.19 kg; P = 0.008), appendicular skeletal muscle mass (0.997 kg; P = 0.005), and skeletal muscle index (0.428 kg/m²; P = 0.025). RT reduced fatigue and improved sleep quality and psychological symptoms (P < 0.05), but had no effect on cognition or overall quality of life. HMB modestly increased phase angle (0.367; P = 0.020) and reduced fatigue (–1.069 points, P = 0.005), but had no effect on other outcomes; hyperglycemia occurred in 3 of 134 patients receiving HMB. No interaction between RT and HMB was detected. CONCLUSIONS: This expanded trial provides novel evidence that RT not only improves physical function but also increases muscle mass, enhances patient-reported outcomes, and lowers 6- and 12-month mortality in critically ill patients. HMB supplementation offered only modest effects on phase angle and fatigue, with no synergistic benefit when combined with RT. TRIAL REGISTRATION: ChiCTR2200057685 ( https://www.chictr.org.cn/ ) was registered on March 15th, 2022.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Wu T, Wei Y, Xiong J, et al. Resistance training and β-hydroxy-β-methylbutyrate for functional recovery in critical illness: a multicenter 2 × 2 factorial randomized trial. Crit Care. 2025. PMID: 41102810. doi:10.1186/s13054-025-05660-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。